Abstract

Development of KSQ-4279 as a first-in-class USP1 inhibitor for the treatment of BRCA-deficient cancers

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call